Genzyme Convenes 1st International Gaucher Conference on Bone Disease

  Genzyme Convenes 1st International Gaucher Conference on Bone Disease

Thought leaders convene in Rio de Janeiro to discuss clinical data on bone in
                        patients with Gaucher disease

Business Wire

CAMBRIDGE, Mass. -- July 1, 2013

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that
the first international meeting focused on bone disease in patients with
Gaucher disease will take place July 5 and 6 in Rio de Janeiro, Brazil. This
meeting will bring together over 100 physicians and researchers from around
the world, with the goal of improving clinical care and shaping the future
direction of research specific to bone disease.

Sponsored by Genzyme, this meeting is chaired by Pramod Mistry, MD, PhD,
Professor of Medicine and Pediatrics and the Director of National Gaucher
Disease Treatment Center at Yale University School of Medicine, New Haven,
Connecticut.

Among the topics for discussion:

  *Pathophysiology of bone disease in Gaucher disease
  *Biomarkers and bone turnover markers
  *Radiological assessment of bone disease
  *Management of bone disease in children and adults

“Impaired bone health is widely recognized as one of the major contributors to
reduced quality of life in patients with Gaucher disease,” said Genzyme’s Head
of Rare Diseases, Rogerio Vivaldi, MD. “This meeting brings together in Rio
international experts from across a wide array of scientific and clinical
disciplines to learn about the latest research, share experiences, and foster
new collaborative relationships.”

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies
for patients affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the compassion and
commitment of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the lives of the
patients and families we serve. This goal guides and inspires us every day.
Genzyme’s portfolio of transformative therapies, which are marketed in
countries around the world, represents groundbreaking and life-saving advances
in medicine. As a Sanofi company, Genzyme benefits from the reach and
resources of one of the world’s largest pharmaceutical companies, with a
shared commitment to improving the lives of patients. Learn more at
www.genzyme.com.

About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Genzyme^® is the registered trademark of Genzyme Corporation. All rights
reserved.

Sanofi Forward Looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words “expects”, “anticipates”,
“believes”, “intends”, “estimates”, “plans” and similar expressions. Although
Sanofi’s management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group’s
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2012. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.

Contact:

Media Contact:
Genzyme
Lori Gorski, 617-768-9344
Lori.gorski@genzyme.com